ADVERTISEMENT

Why Syngene International Shares Are Up 9% Today

Why Syngene International Shares Are Up 9% Today

Shares of Syngene International jumped over 9 per cent on Thursday after the contract research company closed a deal with Bengaluru-based Strand Life Sciences to purchase the latter's assets related to systems biology, Heptox and pharma bioinformatics services. 

Under this acquisition, Syngene will acquire Strand Life Sciences' target dossier business, rights to NGS data analytics and Sarchitect platforms, supported by a scientific team. However, financial details of the deal were not disclosed by the company. 

Syngene believes this acquisition will complement its existing business and help in future growth. 

"We believe Strand's bioinformatics platforms not only complement our existing integrated service platforms but will also meet our customers growing needs for bioinformatics and data analytic support," Jonathan Hunt, chief executive officer of Syngene International, said in a release to Bombay Stock Exchange. 

Syngene International further said that there are tremendous growth opportunities in the bioinformatics space. According to Transparency Market Research, the global bioinformatics market was estimated at $2.3 billion in 2012 and is forecasted to reach a market size of $9.1 billion in 2018, at a compound annual growth rate (CAGR) of 25.4 per cent, the company said. 

Syngene International shares closed 4.03 per cent at Rs 499.90 compared to 1.03 per cent gain in the broader Nifty.